Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | PRKCG | P05129 | 1/20 | 0.30 |
| ▸ | PRKCB | P05771 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCH | P24723 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21726888 | 0.90 | MAPT (0.33) | MAPTOPRM1ACE2 | |
| SCHEMBL19038153 | 0.79 | CYP1A2 (0.48) | MAPTOPRM1ACE2ALDH1A1KMT2A | |
| SCHEMBL19407061 | 0.79 | IDO1 (0.31) | — | |
| SCHEMBL22500128 | 0.78 | ALDH1A1 (0.47) | MAPTOPRM1ACE2ALDH1A1KMT2A | |
| SCHEMBL11677487 | 0.78 | ALDH1A1 (0.47) | MAPTOPRM1ACE2ALDH1A1KMT2A | |
| SCHEMBL11677049 | 0.78 | ALDH1A1 (0.47) | MAPTOPRM1ACE2ALDH1A1KMT2A | |
| SCHEMBL23128664 | 0.76 | OPRM1 (0.39) | MAPTOPRM1ACE2ALDH1A1KMT2A | |
| SCHEMBL21726809 | 0.76 | APLNR (0.34) | — | |
| SCHEMBL5809132 | 0.75 | GNAO1 (0.47) | MAPTACE2PRKD3PRKCGPRKCB | |
| SCHEMBL23332959 | 0.75 | GNAI3 (0.40) | MAPTOPRM1ACE2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562903-B2 | Bridged piperidine derivatives | PTGDR, HPGDS, PSEN1 | MAPT 295/4885OPRM1 177/4885ACE2 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.